127 related articles for article (PubMed ID: 23864685)
21. Evolution characteristics of dynamic balance disorder over the course of PD and relationship with dopamine depletion.
Gan J; Wu X; Wan Y; Zhao J; Song L; Wu N; Wang H; Yin Y; Liu Z
Front Aging Neurosci; 2022; 14():1075572. PubMed ID: 36816750
[TBL] [Abstract][Full Text] [Related]
22. Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research.
Khan MA; Haider N; Singh T; Bandopadhyay R; Ghoneim MM; Alshehri S; Taha M; Ahmad J; Mishra A
Metab Brain Dis; 2023 Mar; 38(3):873-919. PubMed ID: 36807081
[TBL] [Abstract][Full Text] [Related]
23. Spatiotemporal scaling changes in gait in a progressive model of Parkinson's disease.
Doyle AM; Bauer D; Hendrix C; Yu Y; Nebeck SD; Fergus S; Krieg J; Wilmerding LK; Blumenfeld M; Lecy E; Spencer C; Luo Z; Sullivan D; Brackman K; Ross D; Best S; Verma A; Havel T; Wang J; Johnson L; Vitek JL; Johnson MD
Front Neurol; 2022; 13():1041934. PubMed ID: 36582611
[TBL] [Abstract][Full Text] [Related]
24. Cholinergic Modulation of Locomotor Circuits in Vertebrates.
Le Ray D; Bertrand SS; Dubuc R
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142651
[TBL] [Abstract][Full Text] [Related]
25. Pedunculopontine Nucleus Dysconnectivity Correlates With Gait Impairment in Parkinson's Disease: An Exploratory Study.
Joza S; Camicioli R; Martin WRW; Wieler M; Gee M; Ba F
Front Aging Neurosci; 2022; 14():874692. PubMed ID: 35875799
[TBL] [Abstract][Full Text] [Related]
26. Stepping up to meet the challenge of freezing of gait in Parkinson's disease.
Lewis S; Factor S; Giladi N; Nieuwboer A; Nutt J; Hallett M
Transl Neurodegener; 2022 May; 11(1):23. PubMed ID: 35490252
[TBL] [Abstract][Full Text] [Related]
27. Women in Neuromodulation: Innovative Contributions to Stereotactic and Functional Neurosurgery.
Heiden P; Pieczewski J; Andrade P
Front Hum Neurosci; 2021; 15():756039. PubMed ID: 35126071
[TBL] [Abstract][Full Text] [Related]
28. Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
Bohnen NI; Costa RM; Dauer WT; Factor SA; Giladi N; Hallett M; Lewis SJG; Nieuwboer A; Nutt JG; Takakusaki K; Kang UJ; Przedborski S; Papa SM;
Mov Disord; 2022 Feb; 37(2):253-263. PubMed ID: 34939221
[TBL] [Abstract][Full Text] [Related]
29. Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
Wilson J; Yarnall AJ; Craig CE; Galna B; Lord S; Morris R; Lawson RA; Alcock L; Duncan GW; Khoo TK; O'Brien JT; Burn DJ; Taylor JP; Ray NJ; Rochester L
Mov Disord; 2021 Mar; 36(3):611-621. PubMed ID: 33382126
[TBL] [Abstract][Full Text] [Related]
30. Determinants of seeding and spreading of α-synuclein pathology in the brain.
Henrich MT; Geibl FF; Lakshminarasimhan H; Stegmann A; Giasson BI; Mao X; Dawson VL; Dawson TM; Oertel WH; Surmeier DJ
Sci Adv; 2020 Nov; 6(46):. PubMed ID: 33177086
[TBL] [Abstract][Full Text] [Related]
31. Recent developments in the treatment of Parkinson's Disease.
Stoker TB; Barker RA
F1000Res; 2020; 9():. PubMed ID: 32789002
[TBL] [Abstract][Full Text] [Related]
32. Neurophysiological Correlates of Gait in the Human Basal Ganglia and the PPN Region in Parkinson's Disease.
Molina R; Hass CJ; Sowalsky K; Schmitt AC; Opri E; Roper JA; Martinez-Ramirez D; Hess CW; Foote KD; Okun MS; Gunduz A
Front Hum Neurosci; 2020; 14():194. PubMed ID: 32581744
[TBL] [Abstract][Full Text] [Related]
33. Human decisions about when to act originate within a basal forebrain-nigral circuit.
Khalighinejad N; Priestley L; Jbabdi S; Rushworth MFS
Proc Natl Acad Sci U S A; 2020 May; 117(21):11799-11810. PubMed ID: 32385157
[TBL] [Abstract][Full Text] [Related]
34. Pedunculopontine Nucleus Deep Brain Stimulation Improves Gait Disorder in Parkinson's Disease: A Systematic Review and Meta-analysis.
Lin F; Wu D; Lin C; Cai H; Chen L; Cai G; Ye Q; Cai G
Neurochem Res; 2020 Apr; 45(4):709-719. PubMed ID: 31950450
[TBL] [Abstract][Full Text] [Related]
35. Spinal Cord Stimulation for Freezing of Gait: From Bench to Bedside.
Fonoff ET; de Lima-Pardini AC; Coelho DB; Monaco BA; Machado B; Pinto de Souza C; Dos Santos Ghilardi MG; Hamani C
Front Neurol; 2019; 10():905. PubMed ID: 31507514
[TBL] [Abstract][Full Text] [Related]
36. A Stage-Based Approach to Therapy in Parkinson's Disease.
Carrarini C; Russo M; Dono F; Di Pietro M; Rispoli MG; Di Stefano V; Ferri L; Barbone F; Vitale M; Thomas A; Sensi SL; Onofrj M; Bonanni L
Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31434341
[TBL] [Abstract][Full Text] [Related]
37. Emerging therapies in Parkinson disease - repurposed drugs and new approaches.
Elkouzi A; Vedam-Mai V; Eisinger RS; Okun MS
Nat Rev Neurol; 2019 Apr; 15(4):204-223. PubMed ID: 30867588
[TBL] [Abstract][Full Text] [Related]
38. Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board.
Albin RL; Surmeier DJ; Tubert C; Sarter M; Müller MLTM; Bohnen NI; Dauer WT
Mov Disord; 2018 Dec; 33(12):1871-1875. PubMed ID: 30398673
[No Abstract] [Full Text] [Related]
39. A cell autonomous torsinA requirement for cholinergic neuron survival and motor control.
Pappas SS; Li J; LeWitt TM; Kim JK; Monani UR; Dauer WT
Elife; 2018 Aug; 7():. PubMed ID: 30117805
[TBL] [Abstract][Full Text] [Related]
40. Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
Baufreton J; Milekovic T; Li Q; McGuire S; Moraud EM; Porras G; Sun S; Ko WKD; Chazalon M; Morin S; Normand E; Farjot G; Milet A; Pype J; Pioli E; Courtine G; Bessière B; Bezard E
Mov Disord; 2018 Oct; 33(10):1632-1642. PubMed ID: 29756234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
